Regeneron Pharmaceuticals Inc. buy phonebroker
Start price
24.06.15
/
50%
€458.60
Target price
20.07.15
€490.00
Performance (%)
11.97%
End price
20.07.15
€513.50
Summary
This prediction ended on 20.07.15 with a price of €513.50. The prediction had a final performance of 11.97%. phonebroker has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.000% | 0.000% | 21.054% | -16.677% |
| iShares Core DAX® | 1,50 % | -0,27 % | 5,21 % | 52,59 % |
| iShares Nasdaq 100 | 1,85 % | -0,07 % | 37,79 % | 90,51 % |
| iShares Nikkei 225® | 0,41 % | 4,08 % | 60,70 % | 76,93 % |
| iShares S&P 500 | 1,48 % | 0,78 % | 26,35 % | 66,80 % |
Comments by phonebroker for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Spekulativ kaufen
Gute Nachrichtenlage, schöne Kursentwicklung.
(Vom Mitglied beendet)